ORBIMED ADVISORS LLC

Position in VTGN — Vistagen Therapeutics, Inc.

CIK 1055951 New York, NY

Back to VTGN Full portfolio

Position in VTGN

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$1,744,200

-$275,400 QoQ

Shares Held

3,060,000

0.0% QoQ

Ownership

7.46%

of shares outstanding

% of Portfolio

0.04%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2025

3 quarters on record

Voting authority Sole 46% Shared 0% None 54%

Common Shares in VTGN Over Time

Shares Held

Position Value (USD)

Derivatives in VTGN

reported options exposure · as of Dec 31, 2025

CallValue

$29,832

CallShares

45,200

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

ORBIMED ADVISORS LLC holds $2,871,604,021 across 72 Biotechnology names. VTGN ranks #70 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	EWTX	Edgewise Therapeutics, Inc.	15,518,492	$488,832,498
2	ELVN	Enliven Therapeutics, Inc.	7,959,538	$312,013,889
3	SION	Sionna Therapeutics, Inc.	3,530,702	$141,545,843
4	MBX	MBX Biosciences, Inc.	3,637,887	$108,590,926
5	CRVS	Corvus Pharmaceuticals, Inc.	7,165,006	$104,824,037
6	ARGX	Argenx SE	136,900	$99,971,225
7	CMPX	Compass Therapeutics, Inc.	15,219,994	$80,513,768
8	GPCR	Structure Therapeutics Inc.	1,475,403	$71,114,424

All Filings in VTGN

Export CSV

5 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,744,200	3,060,000	0.0%	Shares	Defined	2026-05-15
2025-12-31	$2,019,600	3,060,000	+6669.9%	Shares	Defined	2026-02-17
2025-12-31	$29,832	45,200	-98.5%	Call	Defined	2026-02-17
2025-09-30	$10,863,000	3,060,000	+6669.9%	Shares	Defined	2025-11-14
2025-09-30	$160,460	45,200	—	Call	Defined	2025-11-14
No filing history on record for this holder in this stock.